Abstract

LIRAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES: A REVIEW

Vishnu Das, Haripriya H. and Sujala Sunil

Abstract

BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. OBJECTIVE: Asses the safety of Liraglutide over other oral hypoglycaemic agents in patient with Cardiovascular complications. METHODS: In this double-blind, placebo controlled trial, in which patients are arranged randomly into control and placebo according to their Glycated haemoglobin levels and their coexisting cardiovascular condition. Control receive liraglutide either 1.8 mg or matching placebo once daily as a subcutaneous injection in addition to standard care. The minimum planned follow-up was 42 months, with a maximum of 60 months of receiving the assigned regimen and the data were analysed for to find the confidence interval. RESULTS: The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group. The most common adverse events leading to the discontinuation of liraglutide were gastrointestinal events. The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group. CONCLUSIONS: In the time-toevent analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.

Keywords: .